CSF chitinase proteins in amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Biochemistry
• Biomarker Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Identifying reliable biomarkers for ALS diagnosis and progression is crucial.
• Chitinase proteins are implicated in inflammatory and neurodegenerative processes.

Purpose of the Study:

• To evaluate cerebrospinal fluid (CSF) levels of chitinase proteins (CHIT1, CHI3L1, CHI3L2) in ALS.
• To assess the diagnostic and prognostic value of these chitinases.
• To explore their correlation with disease progression and clinical features.

Main Methods:

• CSF samples were collected from patients with ALS, primary lateral sclerosis (PLS), ALS mimics, healthy controls, and asymptomatic carriers.
• Chitinase protein levels (CHIT1, CHI3L1, CHI3L2), phosphorylated neurofilament heavy chain (pNFH), and C-reactive protein were measured using ELISA.
• Statistical analyses included comparisons between groups, receiver operating characteristic (ROC) analysis, and correlation studies.

Main Results:

• CSF chitinase levels were significantly elevated in ALS patients compared to healthy controls and ALS mimics.
• Chitinase proteins demonstrated good classifier performance for distinguishing ALS from other conditions, though not superior to pNFH.
• CHIT1 and CHI3L2 levels correlated with disease progression rate, and CHI3L1 with cognitive dysfunction.
• Chitinase levels were longitudinally stable and associated with survival in multivariate models.

Conclusions:

• CSF chitinase proteins show potential as indicators of disease activity and progression in ALS.
• They may offer insights into non-autonomous mechanisms driving motor neuron loss in ALS.
• Their utility as independent diagnostic or stratification biomarkers may be limited, but they could aid in assessing responses to therapies targeting neuroinflammation.